Personalized Medicine in HCV Infection. A Prospective, Multicenter, Epidemiological Study to Evaluate the Prevalence of Hepatitis C Infection in Spain in 2015 (PREVHEP)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12,246
- 试验地点
- 3
- 主要终点
- Serum Anti-HCV
研究概览
简要总结
The hypothesis of this investigation stresses that the current understanding of the prevalence of HCV infection in the general population and in different subgroups will serve to lay out medium- and long-term measures for action geared toward reducing the disease burden through preventive, research, screening and therapeutic measures.
Aim: To determine the prevalence of seropositivity and chronic infection with the HCV and to analyze the associated factors. To analyze and infer different screening strategies for HCV infection based on the at-risk groups/cohorts of elevated prevalence detected. to assess the efficiency of screening strategies and the subsequent cost-effectiveness of treatment in the general population
详细描述
Design of the study: Seroepidemiological and virological study of cross-sectional population-based.
Patients and sampling: The study population has been distributed in groups according to age (20-34; 35-49; 50-74 years) and sex. In order to select a representative sample of this overall population, three Spanish regions will be selected on the basis of their different HCV-related hospitalisation rates defined as follows: high, >120 cases/100,000 inhabitants (Madrid); medium, 90-119 cases/100,000 inhabitants (Cantabria); or low, <90 cases/100,000 inhabitants (Valencia).
The participants will be selected through a random, representative sample using our two-stage conglomerate sampling with stratification of the First-Stage Units. These FSUs are made up by the Basic Health Areas (Health Centers). The Second-Stage Units are made up by the individuals. The stratification criteria used in the first stage will be the socioeconomic status-rural/urban environment. The selection of sample elements will be carried out through simple random sampling from the healthcare card database pertaining to the selected Health Centers. A sequence of random, computer-generated numbers will be obtained.
Sample size: In order to achieve an accuracy of 0.4% in the estimate of a percentage through a two-tailed 95% confidence interval, assuming the prevalences indicated by age strata in the general Spanish population (0.6%, 1.9% and 2.7% respectively), a total of 12,263 subjects distributed as follows: 1,456 aged 20-34 years, 4,476 aged 35-49 years and 6,331 aged 50-74 years.
Anticipating an uptake of 9-15%,21 following invitation via telephone, between 81,753 and 136,255 subjects distributed over the three regions needed to be contacted at random.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 20 Years 至 74 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients between 20 and 74 who have health card in each of the autonomous communities studied.
- •They agree to participate, understand and give informed consent.
排除标准
- •Do not meet the criteria above.
结局指标
主要结局
Serum Anti-HCV
时间窗: 1 day
Anti-HCV seroprevalence
次要结局
- HCV RNA viral load(1 day)
- Activity and professional qualifications(1 day)
- Blood pressure (mmHg)(1 day)
- Alkaline Phosphatase (AP)(1 day)
- LDL Cholesterol(1 day)
- Sexual behaviour(1 day)
- Number of sexual partners(1 day)
- Weight (kg)(1 day)
- BMI(1 day)
- AST(1 day)
- GGT (Gammaglutamyl transferase)(1 day)
- HDL Cholesterol(1 day)
- Serum HBsAg(1 day)
- Birth date(1 day)
- Sex(1 day)
- Nosocomial risk score(1 day)
- History of previous check of HCV/HBV exposure(1 day)
- ALT(1 day)
- Serum Albumin(1 day)
- Hemoglobin(1 day)
- Residence time in Spain(1 day)
- Educational level(1 day)
- Abdominal perimeter (cm)(1 day)
- Bilirubin(1 day)
- Triglycerides(1 day)
- Nationality(1 day)
- Lifestyle habit/risk factor score(1 day)
- Height (cm)(1 day)
- Waist perimeter (cm)(1 day)
- Total Cholesterol(1 day)
- White blood cell count (WBC or leukocyte count)(1 day)
- Platelets(1 day)
- INR(1 day)
- kPa in Fibroscan(1 day)
